CAR-T immune therapies could be effective against solid tumors if the right targets are identified, a new study led by University of Illinois Urbana-Champaign researchers suggests. The researchers ...

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors. Now, a new form of highly sensitive CAR T cells aims to overcome one of the biggest barriers ...

The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.

CAR-T therapy's cost per QALY is approximately $100,000, with consistent results across PSM, STM, and DES models. DES uniquely incorporates wait time, significantly affecting CAR-T's ...